Triple Cure ART+ bnAb+LL needs 1 thing: Delivery
Post# of 149688
(Total Views: 1052)
Posted On: 01/26/2025 7:50:37 AM
Triple Cure ART+ bnAb+LL needs 1 thing:
Delivery.
Dr.'s Haigwood & Sacha started in 2016 on resevoir.
BMGF funded the monkey models.
2018 they began working with ART.
2018 BMGF opened their Frontiers Program on Stem cells with Dr. McClune & Dr. Deeks assisting.
Dr. Deeks us to worked for Cytodyn.
Also during Covid on a study with Dr. Sacha & others.
July 11, 2022 $5m grant to Cytodyn:
"This gene therapy will also require a new delivery modality. The grant will fund the design of synthetic novel AAV vectors specific for T and B cells, with the goal of facilitating long-term expression of leronlimab by the body’s own T and B cells.
https://www.biospace.com/cytodyn-highlights-n...leronlimab
Oct 7th, 2024:
https://www.cytodyn.com/newsroom/press-releas...ronlimabs0
12/1/2023:
Patent applications on Long Acting Leronlimab & AAV
Patents published on 11/28/2024.
Dec. 17th, 2024 Dr. J:
"We also continue to make progress on the development of a long-acting formulation of leronlimab that should provide greater patient convenience and help secure additional patent protection for the Company."
From 2018, two different Hiv cure routes were taken.
Cytodyn, Dr. Sacha, LL & LL-PLS won due to:
FcRn.
PreP.
Latch.
Blocking.
Non-toxic
AAV Vector
Breastfeeding.
ART+bNab+LL
( that's alot of science )
An easily administered, non-toxic, single shot, that finally allows accessing underserved region needs.
GF/ViiV (GSK ) & WH for Hiv.
Time to write Agreement checks for licensing, royalties, trials, 1st right refusals, marketing & a LL manufacturing site.
Gates Ventures for Alzheimer’s.
Gates Vascular Institute for Pulmonary Fibrosis.
Delivery.
Dr.'s Haigwood & Sacha started in 2016 on resevoir.
BMGF funded the monkey models.
2018 they began working with ART.
2018 BMGF opened their Frontiers Program on Stem cells with Dr. McClune & Dr. Deeks assisting.
Dr. Deeks us to worked for Cytodyn.
Also during Covid on a study with Dr. Sacha & others.
July 11, 2022 $5m grant to Cytodyn:
"This gene therapy will also require a new delivery modality. The grant will fund the design of synthetic novel AAV vectors specific for T and B cells, with the goal of facilitating long-term expression of leronlimab by the body’s own T and B cells.
https://www.biospace.com/cytodyn-highlights-n...leronlimab
Oct 7th, 2024:
https://www.cytodyn.com/newsroom/press-releas...ronlimabs0
12/1/2023:
Patent applications on Long Acting Leronlimab & AAV
Patents published on 11/28/2024.
Dec. 17th, 2024 Dr. J:
"We also continue to make progress on the development of a long-acting formulation of leronlimab that should provide greater patient convenience and help secure additional patent protection for the Company."
From 2018, two different Hiv cure routes were taken.
Cytodyn, Dr. Sacha, LL & LL-PLS won due to:
FcRn.
PreP.
Latch.
Blocking.
Non-toxic
AAV Vector
Breastfeeding.
ART+bNab+LL
( that's alot of science )
An easily administered, non-toxic, single shot, that finally allows accessing underserved region needs.
GF/ViiV (GSK ) & WH for Hiv.
Time to write Agreement checks for licensing, royalties, trials, 1st right refusals, marketing & a LL manufacturing site.
Gates Ventures for Alzheimer’s.
Gates Vascular Institute for Pulmonary Fibrosis.
(7)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼